BiotechTube
AmMax Bio

AmMax Bio

San Francisco, United States· Est.
ammaxbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

AmMax Bio is a private, clinical-stage biotech leveraging a clinically validated anti-CSF1R antibody platform to build a differentiated oncology pipeline. Its lead asset, AMB-066, is a monoclonal antibody in a Phase 2 proof-of-concept study for colorectal cancer minimal residual disease (CRC MRD), supported by a safety profile established across six prior clinical trials. The company, founded by an experienced entrepreneur with a successful track record and in partnership with Amgen, is targeting significant commercial opportunities in oncology with a pipeline that also includes an ADC and another mAb for various solid tumors and hematologic malignancies.

Oncology

Technology Platform

A CSF1R-targeting platform built around a monoclonal antibody with a well-established safety profile from six prior clinical trials, used to develop mAbs and ADCs for oncology.

Funding History

1
Total raised:$25M
Series A$25M

Opportunities

The lead program in Colorectal Cancer Minimal Residual Disease (CRC MRD) addresses a large, unmet need with a multi-billion dollar market potential for a treatment that can prevent recurrence.
The validated safety of the core CSF1R antibody platform de-risks development and enables rapid exploration of new indications and drug formats, like ADCs, for other high-value oncology markets.

Risk Factors

The company faces significant clinical risk, as the efficacy of its lead asset in the challenging MRD setting is unproven.
As a private, pre-revenue biotech, it is dependent on successful fundraising in a competitive capital environment.
The oncology landscape is crowded, with potential competition from larger firms targeting similar pathways and indications.

Competitive Landscape

The CSF1R and tumor microenvironment space is competitive, with several companies exploring macrophage modulation for cancer. AmMax's differentiation lies in the specific application of its anti-CSF1R antibody for CRC MRD and its advanced safety profile. It will compete with other MRD-directed therapies and broader oncology immunotherapies from large pharma and biotech.

More companies in Biologics / Biosimilars →More companies in United States →